Skip to Content

Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case

TOKYO and RIDGEFIELD, Conn., November 08, 2007 /PRNewswire/ -- Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. (a subsidiary of Boehringer Ingelheim Corporation) announced today that the two companies have reached a settlement agreement with Ranbaxy to enter into a stipulation of dismissal of the pending U.S. litigation with regard to U.S. Patent No. 4,703,063 for Flomax(R) (tamsulosin hydrochloride) capsules, a treatment for the signs and symptoms of benign prostatic hyperplasia (BPH).

As a result of this settlement, the case will be dismissed without prejudice. The settlement of the litigation provides Ranbaxy with the opportunity to launch a generic tamsulosin hydrochloride product on March 2, 2010, prior to the expiration of pediatric exclusivity if such is granted by the FDA. Further terms of the settlement will not be disclosed.

    For more information, please contact:

    Kate O'Connor, Communications & Public Relations

    Boehringer Ingelheim Pharmaceuticals, Inc.

    Tel: 203-791-6250

    Mobile: 917-446-7400

    Astellas Pharma Inc.

    Corporate Communications

    Tel: +81-3-3244-3201

    Fax: +81-3-5201-7473

CONTACT: Kate O'Connor, Communications & Public Relations of BoehringerIngelheim Pharmaceuticals, Inc., Tel, +1-203-791-6250, Mobile,+1-917-446-7400; or Corporate Communications of Astellas Pharma Inc., Tel,+81-3-3244-3201, Fax, +81-3-5201-7473

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: November 2007